| Wissenschaftl. Titel | A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation |
| Erkrankung |
Thorax:
Nicht-kleinzelliges Lungenkarzinom:
Erstlinie
|
| Molekularer Marker |
EGFR ex20ins |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (M, Gauting) Weiterführende Informationen (NIH) |
erstellt 16.05.2024 Data entry III CCP
geändert 16.05.2024 Data entry III CCP